drugset / Trial / NCT04471480
TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Controlled Clinical Study of TC/PD-1 Inhibitors Combined With anlotinib as First-line Treatment for Advanced ESCC
Timeline
- Start
- 2020-09-01
- Primary completion
- 2022-08-31
- Completion
- 2023-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |